zoledronic acid has been researched along with Bone Fractures in 185 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 62 (33.51) | 29.6817 |
| 2010's | 97 (52.43) | 24.3611 |
| 2020's | 26 (14.05) | 2.80 |
| Authors | Studies |
|---|---|
| Bastounis, A; Davis, S; Gittoes, N; Langley, T; Leonardi-Bee, J; Paskins, Z; Sahota, O | 1 |
| Barbary, R; Cameron, M; Sahota, A; Sahota, O; Stewart, AM | 1 |
| Fan, T; Li, W; Ning, Z; Wang, J; Wang, M; Wen, A; Yang, Z; Yao, M; Zhang, W | 1 |
| Balzarini, L; Berruti, A; Carrone, F; Cosentini, D; Farina, D; Lania, AG; Mazziotti, G; Pedersini, R; Pigni, S; Simoncini, EL; Torrisi, R; Vena, W; Zambelli, A | 1 |
| Bartsch, R; Borchert, J; Hadji, P; Kossack, N; O'Kelly, J; Pignot, M | 1 |
| Bastin, S; Bolland, MJ; Gamble, GD; Horne, AM; Mihov, B; Reid, IR | 1 |
| Hafeez, S; Ibrahim, MN; Khoso, ZA; Laghari Br, TM; Raza, SJ; Riaz, M | 1 |
| Gam, S; Gram, B; Hansen, SG; Hermann, AP; Juhl, CB | 1 |
| McConnell, M; Shieh, A | 1 |
| Chang, AB; Conwell, LS; Jeffery, TC | 1 |
| Diffenderfer, BW; Pearman, L; Pyrih, N; Wang, Y; Williams, SA | 1 |
| Bolster, MB; Fan, W; Leder, BZ | 1 |
| Arora, T; Balasubramanian, A; Bradbury, BD; Curtis, JR; Kim, M; Lin, TC; O'Kelly, J; Spangler, L; Stad, RK; Zhao, H | 1 |
| Bhadada, SK; Dhiman, V; Gopinathan, NR; McAlister, WH; Whyte, MP | 1 |
| Bolster, MB; Fan, W; Franco-Garcia, E; Leder, BZ; Ly, TV; Mannstadt, M | 1 |
| Atallah, ÁN; Civile, VT; Gazoni, FM; Santos, FC; Trevisani, VFM | 1 |
| Corbetta, S; Degradi, C; Dito, G; Guabello, G; Longhi, M; Lugaresi, M | 1 |
| Li, YF; Luo, C; Qu, XL; Sheng, ZF; Tian, L; Wang, QY; Xu, LL; Yang, YY; Yue, C | 1 |
| Alves Coelho, MC; Brasil d'Alva, C; Gehrke, B; Madeira, M | 1 |
| Hald, JD; Javaid, MK; Keerie, C; Lam, W; Langdahl, BL; Osborne, P; Ralston, SH; Walsh, J; Weir, CJ | 1 |
| Anastasilakis, AD; Appelman-Dijkstra, NM; Makras, P; Papapoulos, SE; Polyzos, SA | 1 |
| Hsieh, CY; Huang, HK; Sung, SF | 1 |
| Akahoshi, S; Fuse, Y; Katae, Y; Kawasaki, M; Kondo, H; Ogawa, T; Okazaki, Y; Okimoto, N; Sakai, A; Tsukamoto, M; Yamanaka, Y; Yoshioka, T | 1 |
| Bastin, S; Bolland, MJ; Gamble, GD; Horne, AM; Mihov, B; Reid, IR; Stewart, A | 1 |
| Ekbote, V; Karguppikar, MB; Khadilkar, A; Khadilkar, V | 1 |
| He, B; Quan, ZX; Zhang, MZ; Zhao, JQ | 1 |
| Hellig, J; Stevens, Z | 1 |
| Abi-Hanna, D; Baldock, PA; Bassett, JHD; Cheng, TL; Croucher, PI; Fairfield, H; Falank, C; Ghobrial, IM; Hose, D; Kneissel, M; Kramer, I; Le, LMT; Little, DG; McDonald, MM; Mohanty, ST; Morse, A; Oyajobi, BO; Pettitt, JA; Phan, TG; Reagan, MR; Seckinger, A; Simic, MK; Terry, RL; Vanderkerken, K; Williams, GR; Youlten, SE | 1 |
| Intorcia, M; Karlsson, L; Mesterton, J; Overbeek, J; Ström, O; Tepie, MF | 1 |
| Bahi-Buisson, N; Brailly-Tabard, S; Célestin, E; Charles, P; Durand, E; Fontaine, I; Lambert, AS; Linglart, A; Miladi, L; Rothenbuhler, A; Trabado, S; Wicart, P | 1 |
| Djulbegovic, B; Kumar, A; Mhaskar, R; Miladinovic, B | 1 |
| Bech, M; Guizar-Sicairos, M; Isaksson, H; Mathavan, N; Schaff, F; Tägil, M; Turunen, MJ | 1 |
| Jiang, Y; Li, L; Liu, Y; Lv, F; Song, Y; Wang, O; Xia, W; Xing, X; Xu, X | 1 |
| Bellampalli, R; Didel, S; Kirpal, H; Miyanath, S; Mullapudi, N; Panigrahi, I; Rao, S | 1 |
| Bell, R; Brown, J; Cameron, D; Coleman, R; Dodwell, D; Hinsley, S; Marshall, H; Wilson, C | 1 |
| Rosen, CJ | 1 |
| Ben-Bassat, A; Giladi, M; Haitin, Y; Kapelushnik, N; Khananshvili, D; Lisnyansky, M; Loewenstein, A; Marom, M | 1 |
| Djulbegovic, B; Mhaskar, R | 1 |
| Leong, I | 1 |
| Brezin, F; Dousset, B; Feillet, F; Hernandez, M; Lambert, L; Renard, E; Weryha, G; Wiedemann, A | 1 |
| Bastin, S; Bolland, MJ; Gamble, GD; Garratt, E; Horne, AM; Mihov, B; Reid, IR; Stewart, A; Wiessing, KR; Wong, S | 1 |
| Chavarot, N; Flamant, M; Tabibzadeh, N; Vidal-Petiot, E | 1 |
| Hagino, N; Nango, E; Suzuki, S | 1 |
| Tufan, F | 1 |
| Chattopadhyay, A; Jain, S | 1 |
| Gamble, GD; Horne, AM; Reid, IR | 1 |
| de Jongh, RT; Smit, DL; Zillikens, MC | 1 |
| Chen, W; Huang, X; Jiang, H; Lin, R; Wu, C; Wu, J; Zhang, X; Zhu, B | 1 |
| Sugiyama, T | 1 |
| Crandall, CJ; Ensrud, KE | 1 |
| Allen, MR; Berman, A; Powell, KM; Pulliam, A; Skaggs, C; Wallace, JM | 1 |
| Carr, A; Ebeling, P; Hoy, J; Kerr, SJ; Martinez, E; Pocock, N; Richardson, R; Rojas, J | 1 |
| Aft, R; Brufsky, AM; Coleman, RE; Eidtmann, H; Gnant, M; Lind, P; Mauri, D; Polyzos, NP; Swenson, K; Tevaarwerk, AJ; Valachis, A | 1 |
| Bai, H; Guo, A; Jing, D; Yin, S | 1 |
| Cavo, M; Dimopoulos, MA; Drake, MT; Durie, BG; García-Sanz, R; Jurczyszyn, A; Leleu, X; Lentzsch, S; Merlini, G; Morgan, G; Munshi, N; Raje, N; Rajkumar, SV; Reiman, T; Roodman, GD; Sezer, O; Shimizu, K; Spencer, A; Terpos, E; Turesson, I | 1 |
| Coleman, RE; Fizazi, K; Galsky, MD; Gartrell, BA; Miller, K; Saad, F; Sternberg, CN | 1 |
| Cure, E; Cure, MC; Yuce, S | 1 |
| Biggin, A; Briody, J; Cowell, CT; Munns, CF; Ooi, HL | 1 |
| Anitua, E; Begoña, L; Cobos, R; Orive, G; Serrano, AJ | 1 |
| Gore, E; Kachnic, LA; Kim, HE; Lawton, CA; Martin, AG; Nabid, A; Pugh, SL; Shah, AB; Smith, M; Tai, P | 1 |
| Diab, DL; Watts, NB | 1 |
| Kasperk, C; Nawroth, PP; Spiegel, R | 1 |
| Buffat, H; Cavelti, A; Lippuner, K; Perrelet, R; Popp, AW; Senn, C; Windolf, M | 1 |
| Rizzoli, R; Uebelhart, B | 2 |
| Fabiny, A | 1 |
| Bouvet, A; Caruba, T; Pouchot, J; Sabatier, B; Savoldelli, V | 1 |
| Black, DM; Boonen, S; Cauley, JA; Cosman, F; Cummings, SR; Eastell, R; Palermo, L; Reid, IR | 1 |
| Isaksson, H; Perdikouri, C; Tägil, M | 1 |
| Chen, LX; Feng, SQ; Li, YL; Ning, GZ; Zhang, D; Zhang, TS; Zhou, ZR | 1 |
| Aglan, MS; El Banna, RA; Elnashar, M; Ibrahim, MM; Otaify, GA; Temtamy, SA | 1 |
| Adami, S; Gatti, D; Rossini, M; Viapiana, O | 1 |
| Brüel, A; Henriksen, K; Thomsen, JS; Vegger, JB; Wendelboe, MH | 1 |
| Abdel-Rahman, O | 1 |
| Khandelwal, N; Kumar, C; Meena, BL; Panigrahi, I; Somasekhara Aradhya, A | 1 |
| Mészaros, Á; Veszelyné Kotán, E | 1 |
| Alcántara-Montiel, JC; Arce-Cano, M; García-Campos, J; Lugo Reyes, SO; Sánchez-Sánchez, LM; Staines Boone, AT | 1 |
| Jiang, Y; Li, M; Liu, Y; Lv, F; Ma, DD; Song, LJ; Wang, JW; Wang, JY; Wang, O; Xia, WB; Xing, XP; Xu, XJ | 1 |
| Ceausu, I; Depypere, H; Lambrinoudaki, I; Mueck, A; Pérez-López, FR; Rees, M; Senturk, LM; Simoncini, T; Stevenson, JC; Stute, P; Trémollieres, FA; van der Schouw, YT | 1 |
| Inderjeeth, AJ; Inderjeeth, CA; Raymond, WD | 1 |
| Dhillon, S | 1 |
| Kenkre, JS | 1 |
| Alibhai, SMH; Emmenegger, U; Finelli, A; Hotte, SJ; Morgan, SC; Walker-Dilks, C; Winquist, E; Zukotynski, K | 1 |
| Duan, Z; Fang, S; Giordano, SH; Goodwin, JS; Hortobagyi, GN; Kuo, YF | 1 |
| Lafage-Proust, MH | 1 |
| Hochberg, MC | 1 |
| Fukawa, T; Kamiya, S; Wada, S | 1 |
| Amanata, N; He, LH; Little, DG; Swain, MV | 1 |
| Deeks, ED; Perry, CM | 1 |
| Body, JJ | 2 |
| Galapi, F; Lambrinoudaki, I; Papadias, K; Papadimitriou, D; Vlachou, S | 1 |
| Black, DM; Boonen, S; Cosman, F; Delmas, PD; Eastell, R; Eriksen, EF; Kendler, D; Mesenbrink, PG; Munoz, F; Watts, NB | 1 |
| Brown, JJ; Zacharin, MR | 1 |
| Bodingbauer, M; Burghuber, C; Györi, G; Kainz, A; Klaushofer, K; Kristo, I; Marschalek, J; Muehlbacher, F; Oberbauer, R; Pakrah, B; Rasoul-Rockenschaub, S | 1 |
| Gruntmanis, U; Piper, PK | 1 |
| Saylor, PJ; Smith, MR | 1 |
| Crawford, BS; Kraut, EH; McNulty, RM; Turowski, RC | 1 |
| Bolland, MJ; Gamble, GD; Grey, AB; Reid, IR | 1 |
| Amir, E; Clemons, M; Josse, R; Ocaña, A; Seruga, B | 1 |
| Boutrus, R; El-Attar, I; El-Hossieny, H; Kader, YA; Nazmy, M; Zaghloul, MS | 1 |
| Nwachukwu, U | 1 |
| Cole, R | 1 |
| Reid, DM | 1 |
| Brown, JE; Coleman, RE; Cook, RJ; Costa, L; Lipton, A | 1 |
| Lee, RJ; Saylor, PJ; Smith, MR | 1 |
| Berenson, JR | 1 |
| Van Poznak, C | 1 |
| Aspy, CB; Bilbao, J; Pugh, A | 1 |
| Bilezikian, JP; Silva, BC | 1 |
| Brown, J; Burkinshaw, R; Coleman, R; Lester, J; Neville-Webbe, H; Winter, M; Woodward, E | 1 |
| de Magalhães Souza Fialho, SC; Heiden, GI; Morato, EF; Neves, FS; Pereira, IA; Toscano, MA; Werner de Castro, GR; Zimmermann, AF | 1 |
| Akehurst, R; Ariely, R; Boonen, S; Brereton, N; Foss, P; Groot, M; Lusa, T | 1 |
| Adachi, JD; Boonen, S; Bucci-Rechtweg, C; Colón-Emeric, CS; Eriksen, EF; Hyldstrup, L; Lyles, KW; Magaziner, JS; Mautalen, C; Moore, KA; Nordsletten, L; Pieper, CF; Recknor, C; Su, G | 1 |
| Hero, M; Mäkitie, O; Toiviainen-Salo, S; Vuorimies, I | 1 |
| Ludwig, H; Zojer, N | 1 |
| Boucher, A; Räkel, A; Ste-Marie, LG | 1 |
| Botteman, MF; Carter, JA; Joshi, AD; Kaura, S | 1 |
| Guo, A; Hatoum, HT; Lin, SJ; Lipton, A; Smith, MR | 1 |
| Henk, HJ; Kaura, S | 2 |
| Henk, HJ; Kaura, S; Teitelbaum, A | 1 |
| Robb-Nicholson, C | 1 |
| Briody, J; McQuade, M; Munns, CF; Ooi, HL | 1 |
| Autio, KA; Morris, MJ; Scher, HI | 1 |
| Henk, H; Kaura, S; Teitelbaum, A | 1 |
| Clark, OA; Djulbegovic, B; Glasmacher, A; Kumar, A; Mhaskar, R; Miladinovic, B; Redzepovic, J; Wheatley, K | 1 |
| Chen, DC; Hai-Bin, X; Sun, XH; Tan, L; Wang, R; Zhang, J; Zhao, HX; Zhao, YL | 1 |
| Eriksen, EF; Halse, J | 1 |
| Barros, ER; de Oliveira, TP; Lazaretti-Castro, M; Saraiva, GL | 1 |
| Houts, AC; Miller, PJ; Namjoshi, M; Schwartzberg, LS; Stepanski, EJ; Walker, MS | 1 |
| Tao, H; Wang, M; Wang, Y; Wang, Z; Yu, X | 1 |
| Cardemil, C; Norlindh, B; Omar, OM; Thomsen, P; Wexell, CL | 1 |
| Locke, FL; Morgan, GJ | 1 |
| Black, DM; Boonen, S; Bucci-Rechtweg, C; Eastell, R; Hue, TF; Lyles, KW; Mesenbrink, P; Reid, IR; Su, G | 1 |
| Bastit, L; El Kouri, C; Guérif, S; Ktiouet, M; Lebret, T; Lortholary, A; Mouysset, JL; Murraciole, X; Slimane, K | 1 |
| Rosenthal, M | 1 |
| Atkins, CD | 1 |
| Lipton, A; Seaman, J; Zheng, M | 1 |
| Chen, BL; Coleman, RE; Dugan, W; Eisenberg, PD; Gordon, DH; Kaminski, M; Major, P; Provencher, L; Rosen, LS; Seaman, J; Simeone, J | 1 |
| Smith, MR | 1 |
| Tanvetyanon, T | 1 |
| Karakiewicz, P; Perrotte, P; Saad, F | 1 |
| Saad, F | 3 |
| Geusens, P; Reid, D | 1 |
| Weingard, KK | 1 |
| Higano, CS | 1 |
| Fallon, MA; Finkelstein, JS; Kantoff, PW; Kaufman, DS; Lee, H; McGovern, FJ; Michaelson, MD; Smith, MR | 1 |
| Dunn, RL; Gilbert, SM; Wei, JT | 1 |
| Black, DM; Boonen, S; Caminis, J; Cauley, JA; Cosman, F; Cummings, SR; Delmas, PD; Eastell, R; Eriksen, EF; Hu, H; Hue, TF; Krasnow, J; Lakatos, P; Leung, PC; Man, Z; Mautalen, C; Mesenbrink, P; Reid, IR; Rosario-Jansen, T; Sellmeyer, D; Tong, K | 1 |
| Compston, J | 1 |
| Black, DM; Cummings, SR; Schwartz, AV | 1 |
| Gondo, T; Hashimoto, T; Matsunaga, T; Shigetomi, M; Sugiyama, T; Suzuki, H; Taguchi, T; Tanaka, H | 1 |
| Berlakovich, G; Bodingbauer, M; Grampp, S; Klaushofer, K; Mühlbacher, F; Oberbauer, R; Pakrah, B; Peck-Radosavljevic, M; Rockenschaub, S; Roschger, P; Silberhumer, G; Steininger, R; Wekerle, T | 1 |
| Body, JJ; Brown, JP; Burckhardt, P; Devogelaer, JP; Eriksen, EF; Fashola, T; Felsenberg, D; Garnero, P; Goemaere, S; Krasnow, J; Lippuner, K; Meunier, PJ; Ortmann, CE; Samsioe, G; Sanna, L; Trechsel, U | 1 |
| Gralow, JR | 1 |
| Geusens, PP; Lems, WF | 1 |
| Bartoletti, R; Cai, T | 1 |
| de Nijs, RN; Westgeest, AA | 1 |
| Aziz, I; Najib, MA | 1 |
| Chang, JT | 1 |
| Camm, J; Karam, R; McClung, M | 1 |
| Kaptoge, S; Poole, KE; Reeve, J | 1 |
| Abrams, K; Adachi, JD; Boonen, S; Colón-Emeric, CS; Eriksen, EF; Hodgson, PK; Horowitz, Z; Hyldstrup, L; Lavecchia, C; Lyles, KW; Magaziner, JS; Mautalen, C; Mesenbrink, P; Moore, KA; Nordsletten, L; Orloff, JJ; Pieper, CF; Recknor, C; Zhang, J | 1 |
| Calis, KA; Pucino, F | 1 |
| Coleman, RE; Cook, RJ; Lipton, A; Major, P; Smith, MR | 1 |
| Chen, YM; Chin, J; Gleason, DM; Saad, F | 1 |
| Hadji, P | 1 |
| Costa, L | 1 |
| Bundred, N; Hadji, P | 1 |
| Kohno, N; Yamada, K | 1 |
| Hay, JE | 1 |
| van den Berg, P | 1 |
| Al-Khalidi, H; Karam, R; Steinbuch, M | 1 |
| Lopez, CA; Tasneem, Z | 1 |
| Badia, X; Chow, E; Costa, L; Lipton, A; Wardley, A | 1 |
| Lewiecki, EM | 1 |
| Chapurlat, RD | 1 |
| Body, JJ; Brandi, ML; Broell, J; Brown, JP; Burckhardt, P; Devogelaer, JP; Di Micco, R; Felsenberg, D; Genazzani, AR; Happ, J; Hooper, MJ; Horowitz, Z; Ittner, J; Jaeger, P; Kaufman, JM; Leb, G; Mallmin, H; Meunier, PJ; Murray, T; Ortolani, S; Reid, IR; Richardson, P; Rubinacci, A; Saaf, M; Samsioe, G; Trechsel, U; Verbruggen, L; Widmer, A | 1 |
| Jenny-Avital, ER | 1 |
57 review(s) available for zoledronic acid and Bone Fractures
| Article | Year |
|---|---|
Comparing medication adherence in patients receiving bisphosphonates for preventing fragility fractures: a comprehensive systematic review and network meta-analysis.
Topics: Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Medication Adherence; Network Meta-Analysis; Zoledronic Acid | 2022 |
Safety of denosumab versus zoledronic acid in the older adults with osteoporosis: a meta-analysis of cohort studies.
Topics: Aged; Bone Density Conservation Agents; Cardiovascular Diseases; Cohort Studies; Denosumab; Diphosphonates; Fractures, Bone; Humans; Osteoporosis; Systematic Reviews as Topic; Zoledronic Acid | 2022 |
Polypharmacy in Osteoporosis Treatment.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Fractures, Bone; Humans; Ibandronic Acid; Osteoporosis; Osteoporotic Fractures; Polypharmacy; Risedronic Acid; Teriparatide; Zoledronic Acid | 2022 |
Bisphosphonates for osteoporosis in people with cystic fibrosis.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Child; Cystic Fibrosis; Diphosphonates; Female; Fractures, Bone; Humans; Musculoskeletal Pain; Osteoporosis; Pamidronate; Quality of Life; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid | 2023 |
Intravenous zoledronate for postmenopausal women with osteopenia and osteoporosis: a systematic review and metanalysis.
Topics: Bone Density; Bone Density Conservation Agents; Brazil; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Zoledronic Acid | 2023 |
Long-term consequences of osteoporosis therapy with bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Quality of Life; Zoledronic Acid | 2023 |
Drug treatment strategies for osteoporosis in stroke patients.
Topics: Bone Density; Bone Density Conservation Agents; Calcium; Dietary Supplements; Female; Fractures, Bone; Humans; Osteoporosis; Randomized Controlled Trials as Topic; Stroke; Vitamin D; Zoledronic Acid | 2020 |
Zoledronic acid and fracture risk: a meta-analysis of 12 randomized controlled trials.
Topics: Atrial Fibrillation; Bone Density; Bone Density Conservation Agents; Fractures, Bone; Humans; Randomized Controlled Trials as Topic; Zoledronic Acid | 2021 |
Bisphosphonates in multiple myeloma: an updated network meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Disease-Free Survival; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid | 2017 |
Bisphosphonates for Patients Diagnosed With Multiple Myeloma.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Randomized Controlled Trials as Topic; Review Literature as Topic; Zoledronic Acid | 2018 |
Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer.
Topics: Bone Density; Bone Density Conservation Agents; Chemotherapy, Adjuvant; Clodronic Acid; Fractures, Bone; Humans; Male; Prostatic Neoplasms; Survival Rate; Zoledronic Acid | 2019 |
Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Diphosphonates; Disease-Free Survival; Female; Fractures, Bone; Humans; Imidazoles; Neoplasm Staging; Osteoporosis; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2013 |
Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Bone; Humans; Hypocalcemia; Imidazoles; Male; Molecular Targeted Therapy; Osteoclasts; Patient Selection; Prostatic Neoplasms; RANK Ligand; Risk Factors; Treatment Outcome; Zoledronic Acid | 2014 |
Systematic review and meta-analysis of the efficacy and safety of alendronate and zoledronate for the treatment of postmenopausal osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Spinal Fractures; Zoledronic Acid | 2013 |
Postmenopausal osteoporosis.
Topics: Accidental Falls; Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Calcitonin; Calcium; Denosumab; Dietary Supplements; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risk Assessment; Risk Factors; Risk Reduction Behavior; Teriparatide; Vitamin D; Zoledronic Acid | 2013 |
The effect of zoledronic acid on the fracture risk in men with osteoporosis.
Topics: Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Osteoporosis; Risk Assessment; Zoledronic Acid | 2014 |
[Osteoporosis].
Topics: Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium; Cardiovascular Diseases; Denosumab; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Rickets; Risk Factors; Zoledronic Acid | 2014 |
Comparison of Bone Mineral Density in Lumbar Spine and Fracture Rate among Eight Drugs in Treatments of Osteoporosis in Men: A Network Meta-Analysis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Hydroxycholecalciferols; Ibandronic Acid; Imidazoles; Lumbar Vertebrae; Osteoporosis; Parathyroid Hormone; Risedronic Acid; Teriparatide; Thiophenes; Zoledronic Acid | 2015 |
The use of bisphosphonates in women: when to use and when to stop.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors; Time Factors; Zoledronic Acid | 2015 |
Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis.
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Denosumab; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Postmenopause; Randomized Controlled Trials as Topic; Time Factors; Zoledronic Acid | 2016 |
[Therapeutic practice of bisphosphonate use and related pharmaceutical issues I].
Topics: Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Clodronic Acid; Diphosphonates; Fractures, Bone; Humans; Hungary; Ibandronic Acid; Imidazoles; Osteoporosis; Pamidronate; Risedronic Acid; Zoledronic Acid | 2016 |
Osteoporosis management in patients with breast cancer: EMAS position statement.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Neoplasm Recurrence, Local; Osteoporosis; Premenopause; Zoledronic Acid | 2017 |
Zoledronic Acid (Reclast
Topics: Animals; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Zoledronic Acid | 2016 |
Bone Health and Bone-targeted Therapies for Prostate Cancer: a Programme in Evidence-based Care - Cancer Care Ontario Clinical Practice Guideline.
Topics: Absorptiometry, Photon; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Evidence-Based Medicine; Fractures, Bone; Humans; Imidazoles; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radium; Randomized Controlled Trials as Topic; Zoledronic Acid | 2017 |
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Male; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Spinal Fractures; Zoledronic Acid | 2008 |
[Newly developed drugs for osteoporosis in overseas and their future roles for the therapy].
Topics: Anabolic Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Bone Resorption; Denosumab; Diphosphonates; Drug Design; Evidence-Based Medicine; Fractures, Bone; Humans; Imidazoles; Indoles; Organometallic Compounds; Osteoporosis; RANK Ligand; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes; Zoledronic Acid | 2008 |
Zoledronic acid: a review of its use in the treatment of osteoporosis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Male; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid | 2008 |
[Update on treatment of postmenopausal osteoporosis].
Topics: Bone Resorption; Calcium; Diphosphonates; Estrogen Replacement Therapy; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Meta-Analysis as Topic; Osteoporosis, Postmenopausal; Patient Compliance; Zoledronic Acid | 2008 |
Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women.
Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Infusions, Intravenous; Osteoporosis, Postmenopausal; Postmenopause; Treatment Outcome; Zoledronic Acid | 2008 |
Management of osteoporosis in the aging male: focus on zoledronic acid.
Topics: Aged; Aged, 80 and over; Aging; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; United States; Zoledronic Acid | 2009 |
Bone health and prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Neoplasms; Clinical Trials as Topic; Denosumab; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Osteoclasts; Prostatic Neoplasms; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Zoledronic Acid | 2010 |
Effect of osteoporosis treatment on mortality: a meta-analysis.
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Organometallic Compounds; Osteoporosis; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Treatment Outcome; Zoledronic Acid | 2010 |
Update on the use of zoledronic acid in the management of osteoporosis.
Topics: Contraindications; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Kidney; Male; Osteoporosis; Osteoporosis, Postmenopausal; Zoledronic Acid | 2010 |
Treatment and prevention of bone complications from prostate cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone and Bones; Bone Density Conservation Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Osteoblasts; Osteoclasts; Prostatic Neoplasms; RANK Ligand; Zoledronic Acid | 2011 |
Therapeutic options in the management of myeloma bone disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Diseases; Clinical Trials as Topic; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Zoledronic Acid | 2010 |
New approaches to the treatment of osteoporosis.
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Cathepsin K; Denosumab; Diphosphonates; Drug Therapy, Combination; Duodenum; Female; Fractures, Bone; Genetic Markers; Humans; Imidazoles; Osteoporosis; Parathyroid Hormone; Randomized Controlled Trials as Topic; RANK Ligand; Selective Estrogen Receptor Modulators; Serotonin; Zoledronic Acid | 2011 |
Zoledronic acid.
Topics: Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Fractures, Bone; Humans; Imidazoles; Zoledronic Acid | 2011 |
Supportive therapy in multiple myeloma.
Topics: Anemia; Blood Transfusion; Bone Diseases; Calcitonin; Clodronic Acid; Diphosphonates; Erythropoietin; Fractures, Bone; Hematinics; Humans; Hypercalcemia; Imidazoles; Multiple Myeloma; Osteoporosis; Pamidronate; Recombinant Proteins; Renal Insufficiency; Zoledronic Acid | 2011 |
Role of zoledronic acid in the prevention and treatment of osteoporosis.
Topics: Age Factors; Aging; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Injections, Intravenous; Osteoporosis; Osteoporosis, Postmenopausal; Risk Factors; Sex Factors; Zoledronic Acid | 2011 |
Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Denosumab; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Organometallic Compounds; Organophosphorus Compounds; Pain Management; Prostatic Neoplasms; Strontium; Zoledronic Acid | 2012 |
Bisphosphonates in multiple myeloma: a network meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Multiple Myeloma; Pamidronate; Randomized Controlled Trials as Topic; Zoledronic Acid | 2012 |
Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: a meta-analysis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2012 |
What is the evidence for the use of bisphosphonate therapy in newly diagnosed multiple myeloma patients lacking bone disease?
Topics: Bone Diseases; Boronic Acids; Bortezomib; Dexamethasone; Diphosphonates; Fatigue; Fractures, Bone; Humans; Imidazoles; In Situ Hybridization, Fluorescence; Lenalidomide; Magnetic Resonance Imaging; Male; Middle Aged; Multiple Myeloma; Proteinuria; Pyrazines; Randomized Controlled Trials as Topic; Thalidomide; Time Factors; Translocation, Genetic; Treatment Outcome; Zoledronic Acid | 2012 |
Zoledronic acid: an advance in tumour bone disease therapy and a new hope for osteoporosis.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Multiple Myeloma; Osteoporosis; Randomized Controlled Trials as Topic; Zoledronic Acid | 2003 |
Osteoclast-targeted therapy for prostate cancer.
Topics: Adult; Aged; Androgens; Bone Density; Bone Neoplasms; Diphosphonates; Drug Resistance, Neoplasm; Fractures, Bone; Humans; Imidazoles; Male; Middle Aged; Osteoclasts; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Zoledronic Acid | 2004 |
The role of bisphosphonates in hormone-refractory prostate cancer.
Topics: Antineoplastic Agents; Bone Density; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2005 |
Newer drug treatments: their effects on fracture prevention.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Calcitonin; Denosumab; Diphosphonates; Fractures, Bone; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Organometallic Compounds; Osteoporosis; Osteoprotegerin; Parathyroid Hormone; RANK Ligand; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Thiophenes; Zoledronic Acid | 2005 |
The role of bisphosphonates in the management of prostate cancer.
Topics: Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Medical Oncology; Orchiectomy; Prostatic Neoplasms; Survival; Zoledronic Acid | 2006 |
Nursing implications of androgen deprivation therapy-associated bone loss.
Topics: Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; Exercise Therapy; Fractures, Bone; Health Promotion; Humans; Imidazoles; Life Style; Male; Morbidity; Nurse's Role; Nursing Assessment; Osteoporosis; Patient Education as Topic; Prostatic Neoplasms; Risk Factors; Vitamin D; Zoledronic Acid | 2006 |
Reducing the risk of bone loss associated with breast cancer treatment.
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Risk Factors; Women's Health; Zoledronic Acid | 2007 |
Bisphosphonates: reducing the risk of skeletal complications from bone metastasis.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Neoplasm Staging; Osteoporosis; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2007 |
New research findings on zoledronic acid: survival, pain, and anti-tumour effects.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Pain; Prostatic Neoplasms; Urogenital Neoplasms; Zoledronic Acid | 2008 |
Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
Topics: Aromatase Inhibitors; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Risk Factors; Zoledronic Acid | 2007 |
[Clinical study of bisphosphonates for bone metastasis in breast cancer].
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Osteoclasts; Pain; Pamidronate; Quality of Life; Randomized Controlled Trials as Topic; Zoledronic Acid | 2007 |
Impact of skeletal complications on patients' quality of life, mobility, and functional independence.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Health Status; Humans; Imidazoles; Male; Pain; Prostatic Neoplasms; Quality of Life; Zoledronic Acid | 2008 |
Intravenous zoledronic acid for the treatment of osteoporosis.
Topics: Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Fractures, Bone; Humans; Imidazoles; Infusions, Intravenous; Osteoporosis; Risk Factors; Zoledronic Acid | 2008 |
Single annual injectable treatment for postmenopausal osteoporosis.
Topics: Animals; Bone Density Conservation Agents; Clinical Trials as Topic; Delayed-Action Preparations; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Secondary Prevention; Zoledronic Acid | 2008 |
40 trial(s) available for zoledronic acid and Bone Fractures
| Article | Year |
|---|---|
Zoledronate Reduces Height Loss Independently of Vertebral Fracture Occurrence in a Randomized Trial in Osteopenic Older Women.
Topics: Aged; Body Height; Bone Density; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Quality of Life; Spinal Fractures; Zoledronic Acid | 2022 |
Zoledronic Acid for prevention of bone and muscle loss after BAriatric Surgery (ZABAS)-a study protocol for a randomized controlled trial.
Topics: Absorptiometry, Photon; Bariatric Surgery; Biomarkers; Bone Density; Calcium; Female; Fractures, Bone; Hand Strength; Humans; Lumbar Vertebrae; Male; Muscles; Randomized Controlled Trials as Topic; Zoledronic Acid | 2022 |
Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta.
Topics: Adolescent; Adult; Bone Density; Bone Density Conservation Agents; Fractures, Bone; Humans; Osteogenesis Imperfecta; Pain; Quality of Life; Randomized Controlled Trials as Topic; Teriparatide; Zoledronic Acid | 2023 |
Zoledronate for the Prevention of Bone Loss in Women Discontinuing Denosumab Treatment. A Prospective 2-Year Clinical Trial.
Topics: Aged; Biomarkers; Bone Density; Bone Remodeling; Bone Resorption; Denosumab; Female; Femur Neck; Fractures, Bone; Humans; Middle Aged; Withholding Treatment; Zoledronic Acid | 2019 |
Predictors of Fracture in Older Women With Osteopenic Hip Bone Mineral Density Treated With Zoledronate.
Topics: Aged; Bone Density; Female; Fractures, Bone; Humans; Odds Ratio; Zoledronic Acid | 2021 |
ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.
Topics: Adolescent; Alendronate; Bone Density; Child; Child, Preschool; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Incidence; Male; Osteogenesis Imperfecta; Time Factors; Treatment Outcome; Zoledronic Acid | 2018 |
Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study.
Topics: Adult; Aged; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Zoledronic Acid | 2018 |
Fracture Prevention with Zoledronate in Older Women with Osteopenia.
Topics: Acute-Phase Reaction; Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Calcium; Dietary Supplements; Double-Blind Method; Female; Fractures, Bone; Humans; Infusions, Intravenous; Intention to Treat Analysis; Iritis; Proportional Hazards Models; Zoledronic Acid | 2018 |
[Zoledronic acid; useful in osteopenia?]
Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Denmark; Double-Blind Method; Female; Follow-Up Studies; Fractures, Bone; Humans; Incidence; Time Factors; Zoledronic Acid | 2019 |
Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV-Infected Adults on Tenofovir: A Randomized, Open-Label Study.
Topics: Adult; Biomarkers; Bone Density; Bone Remodeling; Female; Fractures, Bone; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Zoledronic Acid | 2019 |
Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women.
Topics: Asian People; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Femur; Femur Neck; Follow-Up Studies; Fractures, Bone; Hip; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Spine; Zoledronic Acid | 2013 |
Intravenous zoledronic Acid given every 6 months in childhood osteoporosis.
Topics: Adolescent; Bone Density Conservation Agents; Child; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Male; Osteoporosis; Retrospective Studies; Time Factors; Zoledronic Acid | 2013 |
RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Osteoporosis; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2013 |
Cortical bone loss at the tibia in postmenopausal women with osteoporosis is associated with incident non-vertebral fractures: results of a randomized controlled ancillary study of HORIZON.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Incidence; Osteoporosis, Postmenopausal; Tibia; Zoledronic Acid | 2014 |
Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Osteoporosis; Postmenopause; Risk Assessment; Treatment Outcome; Zoledronic Acid | 2014 |
Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis.
Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Child; Child Development; Child, Preschool; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Injections, Intravenous; Kidney; Liver; Male; Osteogenesis Imperfecta; Osteoporosis; Pamidronate; Treatment Outcome; Zoledronic Acid | 2009 |
Non-persistent effect of short-term bisphosphonate treatment in preventing fractures after liver transplantation.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Zoledronic Acid | 2010 |
A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer.
Topics: Adult; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Egypt; Female; Fractures, Bone; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Pain; Placebo Effect; Prospective Studies; Risk Assessment; Risk Factors; Spinal Cord Compression; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Zoledronic Acid | 2010 |
Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Health Status; Hip Fractures; Humans; Imidazoles; Male; Middle Aged; Quality of Life; Spinal Fractures; Surveys and Questionnaires; Zoledronic Acid | 2011 |
Zoledronic acid treatment in children with osteogenesis imperfecta.
Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Infant; Lumbar Vertebrae; Male; Osteogenesis Imperfecta; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2011 |
Cost-effectiveness of zoledronic acid in the management of skeletal metastases in patients with lung cancer in France, Germany, Portugal, the Netherlands, and the United kingdom.
Topics: Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cost-Benefit Analysis; Diphosphonates; Europe; Fractures, Bone; Health Care Costs; Humans; Hypercalcemia; Imidazoles; Lung Neoplasms; Middle Aged; Quality-Adjusted Life Years; Spinal Cord Compression; Zoledronic Acid | 2011 |
Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta.
Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Infant; Male; Osteogenesis Imperfecta; Pamidronate; Prospective Studies; Treatment Outcome; Zoledronic Acid | 2012 |
Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Hypercalcemia; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paraneoplastic Syndromes; Spinal Cord Compression; Strontium; Zoledronic Acid | 2013 |
The effects of a systemic single dose of zoledronic acid on post-implantation bone remodelling and inflammation in an ovariectomised rat model.
Topics: Animals; Bone Density Conservation Agents; Combined Modality Therapy; Diphosphonates; Female; Fractures, Bone; Imidazoles; Osteitis; Osteogenesis; Ovariectomy; Prostheses and Implants; Rats; Rats, Sprague-Dawley; Treatment Outcome; Zoledronic Acid | 2013 |
Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Incidence; Male; Prospective Studies; Risk; Treatment Outcome; Zoledronic Acid | 2013 |
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Topics: Androgens; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Pain; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2003 |
Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Topics: Androgens; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Pain; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Treatment Outcome; Zoledronic Acid | 2003 |
Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma.
Topics: Aged; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease Progression; Female; Fractures, Bone; Humans; Imidazoles; Kidney Neoplasms; Male; Middle Aged; Placebos; Retrospective Studies; Spinal Cord Compression; Treatment Outcome; Zoledronic Acid | 2003 |
Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.
Topics: Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Carcinoma; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fractures, Bone; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteolysis; Pamidronate; Risk Factors; Spinal Cord Compression; Zoledronic Acid | 2004 |
Clinical benefit of zoledronic acid for the prevention of skeletal complications in advanced prostate cancer.
Topics: Aged; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Incidence; Male; Pain; Prostatic Neoplasms; Quality of Life; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid | 2005 |
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Boston; Diphosphonates; Drug Administration Schedule; Fractures, Bone; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Prostatic Neoplasms; Time Factors; Treatment Outcome; Zoledronic Acid | 2007 |
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Biomarkers; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Incidence; Infusions, Intravenous; Osteoporosis, Postmenopausal; Risk; Spinal Fractures; Zoledronic Acid | 2007 |
Prophylactic bisphosphonate treatment prevents bone fractures after liver transplantation.
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Prospective Studies; Survival Analysis; Zoledronic Acid | 2007 |
Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis.
Topics: Adult; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Osteoporosis, Postmenopausal; Treatment Outcome; Zoledronic Acid | 2007 |
[Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Female; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Infusions, Intravenous; Osteoporosis, Postmenopausal; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2007 |
Zoledronic acid and clinical fractures and mortality after hip fracture.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Survival Analysis; Vitamin D; Zoledronic Acid | 2007 |
Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
Topics: Biomarkers; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Collagen Type I; Creatinine; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Injections, Intravenous; Male; Multiple Myeloma; Osteoclasts; Osteolysis; Pamidronate; Peptides; Retrospective Studies; Risk Assessment; Survival Rate; Treatment Outcome; Zoledronic Acid | 2007 |
Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Pain; Prostatic Neoplasms; Retrospective Studies; Zoledronic Acid | 2007 |
How effective is bisphosphonate treatment for preventing bone fractures after liver transplantation?
Topics: Absorptiometry, Photon; Adult; Biomarkers; Body Mass Index; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium Carbonate; Cholecalciferol; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Liver Transplantation; Male; Middle Aged; Prospective Studies; Treatment Outcome; Zoledronic Acid | 2008 |
Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Remodeling; Collagen; Collagen Type I; Creatinine; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Zoledronic Acid | 2002 |
88 other study(ies) available for zoledronic acid and Bone Fractures
| Article | Year |
|---|---|
Safety of zoledronate in older patients at high risk of fracture with reduced renal function.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Humans; Kidney; Renal Insufficiency; Zoledronic Acid | 2022 |
Real-World Effectiveness of Denosumab and Bisphosphonates on Risk of Vertebral Fractures in Women with Breast Cancer Undergoing Treatment with Aromatase Inhibitors.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Child; Child, Preschool; Denosumab; Diphosphonates; Female; Fractures, Bone; Humans; Prospective Studies; Spinal Fractures; Zoledronic Acid | 2022 |
Real-world effectiveness of osteoporosis treatments in Germany.
Topics: Bone Density Conservation Agents; Cohort Studies; Denosumab; Diphosphonates; Female; Fractures, Bone; Germany; Humans; Ibandronic Acid; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Zoledronic Acid | 2022 |
Safety and Efficacy of Zoledronic Acid in children with Osteogenesis Imperfecta.
Topics: Bone Density Conservation Agents; Child; Diphosphonates; Female; Fractures, Bone; Humans; Male; Osteogenesis Imperfecta; Treatment Outcome; Zoledronic Acid | 2022 |
Real-World Management of Patients With Osteoporosis at Very High Risk of Fracture.
Topics: Aged; Bone Density Conservation Agents; Female; Fractures, Bone; Humans; Male; Medicare; Osteoporosis; Osteoporotic Fractures; Retrospective Studies; United States; Zoledronic Acid | 2023 |
Response to Letter to the Editor From Riahi and Gruntmanis: "Inpatient Zoledronic Acid and Integrated Orthopedic and Fracture Liaison Services Improve Osteoporosis Treatment Rates".
Topics: Fractures, Bone; Humans; Inpatients; Osteoporosis; Zoledronic Acid | 2023 |
Comparability of Osteoporosis Treatment Groups Among Female Medicare Beneficiaries in the United States.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Fractures, Bone; Humans; Medicare; Osteoporosis; Osteoporosis, Postmenopausal; Retrospective Studies; United States; Zoledronic Acid | 2023 |
Drug-induced osteopetrosis.
Topics: Child; Fractures, Bone; Humans; Osteoclasts; Osteopetrosis; Skull; Zoledronic Acid | 2023 |
Safety of Inpatient Zoledronic Acid in the Immediate Postfracture Setting.
Topics: Acetaminophen; Bone Density Conservation Agents; Calcium; Creatinine; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Inpatients; Zoledronic Acid | 2023 |
Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study.
Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Denosumab; Diphosphonates; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Retrospective Studies; Teriparatide; Zoledronic Acid | 2023 |
Economic evaluation of four treatment strategies for postmenopausal patients with osteoporosis and a recent fracture in mainland China: a cost-effectiveness analysis.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Denosumab; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Postmenopause; Quality-Adjusted Life Years; Teriparatide; Zoledronic Acid | 2023 |
Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Denosumab; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Retrospective Studies; Tartrate-Resistant Acid Phosphatase; Withholding Treatment; Zoledronic Acid | 2020 |
Comprehensive evaluation of bone health using DXA and pQCT in an Indian boy with osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Calcium; Child; Diphosphonates; Fractures, Bone; Humans; Male; Osteogenesis Imperfecta; Tomography, X-Ray Computed; Vitamin D; Zoledronic Acid | 2020 |
Breast cancer therapy and bone.
Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Neoplasm Recurrence, Local; Zoledronic Acid | 2022 |
Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies; Bone Density; Bone Morphogenetic Proteins; Cell Line, Tumor; Diphosphonates; Fractures, Bone; Genetic Markers; Humans; Imidazoles; Mice; Multiple Myeloma; Osteocytes; Osteogenesis; Tumor Cells, Cultured; Zoledronic Acid | 2017 |
Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Imidazoles; Incidence; Middle Aged; Netherlands; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Registries; Risedronic Acid; Risk Factors; Sweden; Treatment Outcome; Zoledronic Acid | 2017 |
Lower incidence of fracture after IV bisphosphonates in girls with Rett syndrome and severe bone fragility.
Topics: Adolescent; Adult; Bone Density; Bone Density Conservation Agents; Calcium; Child; Creatinine; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Incidence; Pamidronate; Rett Syndrome; Young Adult; Zoledronic Acid | 2017 |
The compositional and nano-structural basis of fracture healing in healthy and osteoporotic bone.
Topics: Animals; Bone Density Conservation Agents; Bone Morphogenetic Protein 7; Bony Callus; Diphosphonates; Disease Models, Animal; Fracture Healing; Fractures, Bone; Imidazoles; Osteoporosis; Rats; Scattering, Small Angle; Spectroscopy, Fourier Transform Infrared; Zoledronic Acid | 2018 |
Novel mutation in a family with WNT1-related osteoporosis.
Topics: Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Genetic Variation; Humans; Imidazoles; Infant; Male; Mutation; Osteogenesis Imperfecta; Wnt1 Protein; Zoledronic Acid | 2018 |
A Not-So-New Treatment for Old Bones.
Topics: Bone and Bones; Bone Diseases, Metabolic; Female; Fractures, Bone; Humans; Zoledronic Acid | 2018 |
Reduced Activity of Geranylgeranyl Diphosphate Synthase Mutant Is Involved in Bisphosphonate-Induced Atypical Fractures.
Topics: Crystallography, X-Ray; Dimethylallyltranstransferase; Diphosphonates; Farnesyltranstransferase; Fractures, Bone; Heterozygote; Humans; Models, Molecular; Mutation, Missense; Zoledronic Acid | 2018 |
Zoledronate prevents fractures in osteopenia.
Topics: Aged; Bone Diseases, Metabolic; Female; Fractures, Bone; Humans; Zoledronic Acid | 2018 |
Annual Injection of Zoledronic Acid Improves Bone Status in Children with Cerebral Palsy and Rett Syndrome.
Topics: Adolescent; Bone and Bones; Bone Density; Bone Density Conservation Agents; Cerebral Palsy; Child; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Rett Syndrome; Time Factors; Zoledronic Acid | 2019 |
Biphosphonate Therapy, Risk of Fracture, and Sites of Bone Mineral Density Assessments in Kidney Transplantation.
Topics: Bone Density; Chronic Kidney Disease-Mineral and Bone Disorder; Fractures, Bone; Humans; Kidney Transplantation; Zoledronic Acid | 2019 |
Fracture Prevention with Zoledronate in Older Women with Osteopenia.
Topics: Aged; Bone Diseases, Metabolic; Diphosphonates; Female; Fractures, Bone; Humans; Zoledronic Acid | 2019 |
Fracture Prevention with Zoledronate in Older Women with Osteopenia.
Topics: Aged; Bone Diseases, Metabolic; Diphosphonates; Female; Fractures, Bone; Humans; Zoledronic Acid | 2019 |
Fracture Prevention with Zoledronate in Older Women with Osteopenia.
Topics: Aged; Bone Diseases, Metabolic; Diphosphonates; Female; Fractures, Bone; Humans; Zoledronic Acid | 2019 |
Fracture Prevention with Zoledronate in Older Women with Osteopenia. Reply.
Topics: Aged; Bone Diseases, Metabolic; Diphosphonates; Female; Fractures, Bone; Humans; Zoledronic Acid | 2019 |
Optimal dosing of zoledronate to prevent fractures: improving risk-benefit balance.
Topics: Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Postmenopause; Zoledronic Acid | 2019 |
In older postmenopausal women with osteopenia, zoledronate reduced fragility fractures at 6 years.
Topics: Aged; Bone Diseases, Metabolic; Female; Fractures, Bone; Humans; Postmenopause; Zoledronic Acid | 2019 |
Zoledronate and Raloxifene combination therapy enhances material and mechanical properties of diseased mouse bone.
Topics: Animals; Biomechanical Phenomena; Bone Diseases; Calcification, Physiologic; Cancellous Bone; Diaphyses; Drug Therapy, Combination; Femur; Fractures, Bone; Male; Mice, Inbred C57BL; Raloxifene Hydrochloride; Zoledronic Acid | 2019 |
International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.
Topics: Administration, Intravenous; Bone Density Conservation Agents; Bone Diseases; Clodronic Acid; Combined Modality Therapy; Diphosphonates; Drug Therapy, Combination; Fractures, Bone; Humans; Imidazoles; International Cooperation; Magnetic Resonance Imaging; Medical Oncology; Multiple Myeloma; Osteonecrosis; Outcome Assessment, Health Care; Pamidronate; Positron-Emission Tomography; Practice Guidelines as Topic; Radiotherapy; Tomography, X-Ray Computed; Zoledronic Acid | 2013 |
Severe hypocalcemia associated with zoledronic acid treatment in a patient with a risk of fracture due to drug-induced osteopenia.
Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Female; Fractures, Bone; Humans; Hypocalcemia; Imidazoles; Lupus Erythematosus, Systemic; Middle Aged; Risk; Zoledronic Acid | 2013 |
[Expert group consensus: prevention, diagnosis and treatment of bone loss and osteoporosis in postmenopausal breast cancer patients after aromatase inhibitor therapy].
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Calcium; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Postmenopause; Vitamin D; Zoledronic Acid | 2013 |
Ask the doctor. I've had osteoporosis for several years, and I've been taking alendronate (Fosamax) once a week. I wasn't very good at remembering to take it regularly, so my doctor recently recommended that I start on once-a-year infusions of zoledronic
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Health Behavior; Humans; Imidazoles; Infusions, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Zoledronic Acid | 2014 |
Evaluation of the prescription of osteoporosis treatment after a major osteoporotic fracture.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcium; Dietary Supplements; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; France; Hip Fractures; Humans; Imidazoles; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Prescriptions; Raloxifene Hydrochloride; Retrospective Studies; Thiophenes; Treatment Outcome; Vitamin D; Wrist Injuries; Zoledronic Acid | 2014 |
Characterizing the composition of bone formed during fracture healing using scanning electron microscopy techniques.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Morphogenetic Protein 7; Bone Morphogenetic Proteins; Bony Callus; Calcification, Physiologic; Cell Differentiation; Diphosphonates; Fracture Healing; Fractures, Bone; Imidazoles; Male; Microscopy, Electron, Scanning; Rats, Sprague-Dawley; Zoledronic Acid | 2015 |
Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
Topics: Adolescent; Bone Density; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Infant; Infusions, Intravenous; Male; Osteogenesis Imperfecta; Pain Measurement; Prospective Studies; Severity of Illness Index; Zoledronic Acid | 2016 |
Zoledronate prevents lactation induced bone loss and results in additional post-lactation bone mass in mice.
Topics: Absorptiometry, Photon; Alkaline Phosphatase; Animals; Body Weight; Bone and Bones; Bone Density; Bone Resorption; Diphosphonates; Female; Femur; Fractures, Bone; Imidazoles; Lactation; Mice; Organ Size; Osteogenesis; Tartrate-Resistant Acid Phosphatase; Weaning; X-Ray Microtomography; Zoledronic Acid | 2016 |
Zoledronate for Osteogenesis imperfecta: evaluation of safety profile in children.
Topics: Bone Density; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Infant; Male; Osteogenesis Imperfecta; Prognosis; Retrospective Studies; Safety; Zoledronic Acid | 2016 |
Zoledronate as effective treatment for minimal trauma fractures in a child with STAT3 deficiency and osteonecrosis of the hip.
Topics: Bone Density Conservation Agents; Child; Diphosphonates; Fractures, Bone; Hip; Humans; Imidazoles; Male; Osteonecrosis; STAT3 Transcription Factor; Zoledronic Acid | 2016 |
Novel mutations in FKBP10 in Chinese patients with osteogenesis imperfecta and their treatment with zoledronic acid.
Topics: Adult; Asian People; Base Sequence; Bone Density; Bone Density Conservation Agents; Bone Resorption; Child; Child, Preschool; China; Collagen Type I; Collagen Type I, alpha 1 Chain; Diphosphonates; Female; Fractures, Bone; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; Male; Membrane Proteins; Osteogenesis Imperfecta; Sequence Analysis, DNA; Tacrolimus Binding Proteins; Young Adult; Zoledronic Acid | 2017 |
Medication selection and patient compliance in the clinical management of osteoporosis.
Topics: Australia; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Patient Compliance; Physician-Patient Relations; Reminder Systems; Risedronic Acid; Zoledronic Acid | 2016 |
Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment?
Topics: Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Risk; Zoledronic Acid | 2015 |
Use of intravenous bisphosphonates in older women with breast cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cohort Studies; Diphosphonates; Female; Follow-Up Studies; Fractures, Bone; Humans; Imidazoles; Injections, Intravenous; Multivariate Analysis; Pain; Pamidronate; Prevalence; SEER Program; Survival Rate; United States; Zoledronic Acid | 2008 |
Once-yearly intravenous zoledronate does not impair renal function in postmenopausal women.
Topics: Aged; Bone Density Conservation Agents; Creatinine; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Infusions, Intravenous; Kidney; Middle Aged; Osteoporosis, Postmenopausal; Safety; Zoledronic Acid | 2008 |
The effect of zoledronic acid on the intrinsic material properties of healing bone: an indentation study.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Elasticity; Fracture Healing; Fractures, Bone; Humans; Imidazoles; Models, Statistical; Osteoporosis; Pressure; Rats; Salts; Zoledronic Acid | 2008 |
Effects of yearly zoledronic acid 5 mg on bone turnover markers and relation of PINP with fracture reduction in postmenopausal women with osteoporosis.
Topics: Aged; Biomarkers; Bone Density; Bone Remodeling; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Osteoporosis; Peptide Fragments; Postmenopause; Procollagen; Zoledronic Acid | 2009 |
Corticosteroids: no drug prevention of fractures needed.
Topics: Adrenal Cortex Hormones; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Steroids; Teriparatide; Vitamin D; Zoledronic Acid | 2009 |
Extended use of intravenous bisphosphonate therapy for the prevention of skeletal complications in patients with cancer.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Jaw Diseases; Lung Neoplasms; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Retrospective Studies; Spinal Cord Compression; Time Factors; Treatment Outcome; Zoledronic Acid | 2009 |
Medical oncology: Zoledronic acid for breast cancer therapy-induced bone loss.
Topics: Absorptiometry, Photon; Aromatase Inhibitors; Biomarkers; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Confidence Intervals; Diphosphonates; Female; Fractures, Bone; Health Status Indicators; Humans; Imidazoles; Incidence; Odds Ratio; Risk Factors; Risk Reduction Behavior; Zoledronic Acid | 2010 |
Health trends.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Blood Glucose; Bone Density Conservation Agents; Chemotherapy, Adjuvant; Colonic Neoplasms; Diabetes Mellitus, Type 2; Diphosphonates; Drug Therapy; Dyslipidemias; Enoxaparin; Fibrinolytic Agents; Fractures, Bone; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Imidazoles; Middle Aged; Neoplasm Staging; Pharmacy; Pyrazoles; Pyridones; Salicylates; Treatment Outcome; Venous Thromboembolism; Young Adult; Zoledronic Acid | 2010 |
Postmenopausal osteoporosis: another approach to management.
Topics: Absorptiometry, Photon; Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Medication Adherence; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Risk Assessment; Secondary Prevention; Zoledronic Acid | 2010 |
Prognostic factors for skeletal complications from metastatic bone disease in breast cancer.
Topics: Aged; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Clinical Trials, Phase III as Topic; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Multicenter Studies as Topic; Pain; Pain Measurement; Proportional Hazards Models; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Spinal Cord Compression; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2010 |
Predicting skeletal complications in metastatic breast cancer raises challenges.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Pain; Risk Assessment; Risk Factors; Spinal Cord Compression; Spinal Fractures; Treatment Outcome; Zoledronic Acid | 2010 |
In postmenopausal women with osteoporosis, is zoledronic acid (Reclast) superior in improving T-scores and decreasing fracture rates when compared with placebo?
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Zoledronic Acid | 2010 |
Paget's disease of bone: analysis of 134 cases from an island in Southern Brazil: another cluster of Paget's disease of bone in South America.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone Density Conservation Agents; Brazil; Cluster Analysis; Comorbidity; Deafness; Diphosphonates; Female; Fibrous Dysplasia, Polyostotic; Fractures, Bone; Humans; Hydrocephalus; Imidazoles; Male; Middle Aged; Osteitis Deformans; Polyradiculopathy; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2012 |
The cost effectiveness of zoledronic acid 5 mg for the management of postmenopausal osteoporosis in women with prior fractures: evidence from Finland, Norway and the Netherlands.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Computer Simulation; Cost-Benefit Analysis; Diphosphonates; Female; Finland; Fractures, Bone; Humans; Imidazoles; Middle Aged; Netherlands; Norway; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Treatment Outcome; Zoledronic Acid | 2011 |
Treatment persistence with monthly zoledronic acid is associated with lower risk and frequency of skeletal complications in patients with breast cancer and bone metastasis.
Topics: Adult; Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Middle Aged; Regression Analysis; Zoledronic Acid | 2011 |
Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Databases, Factual; Diphosphonates; Female; Fractures, Bone; Humans; Hypercalcemia; Imidazoles; Insurance Claim Review; Medicare Part C; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; Spinal Cord Compression; United States; Zoledronic Acid | 2012 |
Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Male; Middle Aged; Outcome Assessment, Health Care; Survival Analysis; United States; Urogenital Neoplasms; Zoledronic Acid | 2012 |
Retrospective evaluation of the clinical benefit of long-term continuous use of zoledronic acid in patients with lung cancer and bone metastases.
Topics: Aged; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Lung Neoplasms; Male; Medicare Part C; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; United States; Zoledronic Acid | 2012 |
Ask the doctor. I'm looking for information on Prolia and Reclast as alternatives to Boniva.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Women's Health; Zoledronic Acid | 2011 |
Zoledronic acid improves bone mineral density in pediatric spinal cord injury.
Topics: Bone and Bones; Bone Density; Child; Densitometry; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Myelitis, Transverse; Osteoporosis; Spinal Cord Injuries; Tibia; Treatment Outcome; Zoledronic Acid | 2012 |
Evaluation of the clinical benefit of long-term (beyond 2 years) treatment of skeletal-related events in advanced cancers with zoledronic acid.
Topics: Bone Density Conservation Agents; Bone Diseases; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Neoplasms; Retrospective Studies; Spinal Cord Compression; Zoledronic Acid | 2012 |
[When should bisphosphonate treatment be discontinued?].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Risk Factors; Zoledronic Acid | 2012 |
Relationship between incidence of fracture and health-related quality-of-life in metastatic breast cancer patients with bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Incidence; Middle Aged; Quality of Life; Retrospective Studies; Socioeconomic Factors; Zoledronic Acid | 2013 |
Home-based zoledronic acid infusion therapy in patients with solid tumours: compliance and patient-nurse satisfaction.
Topics: Adult; Aged; Aged, 80 and over; Attitude of Health Personnel; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diphosphonates; Feasibility Studies; Female; Fractures, Bone; Home Infusion Therapy; Humans; Imidazoles; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Nurses, Community Health; Osteonecrosis; Patient Compliance; Patient Satisfaction; Physicians; Prospective Studies; Prostatic Neoplasms; Zoledronic Acid | 2013 |
Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Topics: Analgesics; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Jaw; Male; Necrosis; Osteomyelitis; Osteopetrosis; Pain; Pain Measurement; Pamidronate; Prostatic Neoplasms; Quality of Life; Research Design; Surveys and Questionnaires; Time Factors; Treatment Outcome; Zoledronic Acid | 2005 |
[Osteoporosis and anti-androgenic therapy in case of prostate cancer].
Topics: Androgen Antagonists; Bone Resorption; Diphosphonates; Fractures, Bone; Humans; Imidazoles; Male; Osteoporosis; Prognosis; Prostatic Neoplasms; Risk Factors; Survival; Zoledronic Acid | 2005 |
Annual zoledronic acid: is less more?
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Drug Administration Schedule; Fractures, Bone; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Treatment Outcome; Zoledronic Acid | 2007 |
Re: Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer: C. W. Ryan, D. Huo, L. M. Demers, T. M. Beer and L. V. Lacerna. J Urol 2006; 176: 972-978.
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Risk Factors; Time Factors; Zoledronic Acid | 2007 |
Treatments for osteoporosis - looking beyond the HORIZON.
Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Fractures, Bone; Humans; Imidazoles; Osteonecrosis; Osteoporosis, Postmenopausal; Zoledronic Acid | 2007 |
Alendronate and atrial fibrillation.
Topics: Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Zoledronic Acid | 2007 |
Effects of bisphosphonate treatment on bone repair under immunosuppression using cyclosporine A in adult rats.
Topics: Animals; Biomarkers; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Bone Transplantation; Cyclosporine; Diphosphonates; Drug Interactions; Fractures, Bone; Graft Survival; Imidazoles; Immunosuppressive Agents; Male; Osteogenesis; Osteoporosis; Rats; Rats, Inbred Lew; Tibia; Zoledronic Acid | 2007 |
Bone density in breast cancer: when to intervene?
Topics: Absorptiometry, Photon; Anastrozole; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Diphosphonates; Female; Fractures, Bone; Goserelin; Humans; Imidazoles; Nitriles; Osteoporosis; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles; Zoledronic Acid | 2007 |
Patient quality of life safeguarding: the primary aim in nonmetastatic prostate cancer patients.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Boston; Diphosphonates; Drug Administration Schedule; Fractures, Bone; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Zoledronic Acid | 2007 |
Yearly zoledronic acid in postmenopausal osteoporosis.
Topics: Atrial Fibrillation; Bone Density Conservation Agents; Calcium; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Hypocalcemia; Imidazoles; Osteoporosis, Postmenopausal; Parathyroid Hormone; Zoledronic Acid | 2007 |
Yearly zoledronic acid in postmenopausal osteoporosis.
Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Placebos; Research Design; Zoledronic Acid | 2007 |
Yearly zoledronic acid in postmenopausal osteoporosis.
Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Renal Insufficiency; Zoledronic Acid | 2007 |
Yearly zoledronic acid in postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2007 |
Yearly zoledronic acid in postmenopausal osteoporosis.
Topics: Atrial Fibrillation; Bone Density Conservation Agents; Calcium; Diphosphonates; Female; Fractures, Bone; Humans; Hypocalcemia; Imidazoles; Osteoporosis, Postmenopausal; Parathyroid Hormone; Zoledronic Acid | 2007 |
Zoledronic acid and secondary prevention of fractures.
Topics: Bone Density Conservation Agents; Diphosphonates; Ethics, Research; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Research Design; Zoledronic Acid | 2007 |
A once-yearly IV bisphosphonate for osteoporosis.
Topics: Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Female; Fractures, Bone; Humans; Imidazoles; Infusions, Intravenous; Osteoporosis, Postmenopausal; Treatment Outcome; Zoledronic Acid | 2007 |
Zoledronate, fractures, and mortality after hip fracture.
Topics: Bone Density Conservation Agents; Diphosphonates; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Research Design; Risk; Zoledronic Acid | 2008 |
Zoledronate, fractures, and mortality after hip fracture.
Topics: Bone Density Conservation Agents; Data Interpretation, Statistical; Diphosphonates; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Research Design; Zoledronic Acid | 2008 |
Zoledronate, fractures, and mortality after hip fracture.
Topics: Atrial Fibrillation; Bone Density Conservation Agents; Confounding Factors, Epidemiologic; Diphosphonates; Fractures, Bone; Hip Fractures; Humans; Imidazoles; Zoledronic Acid | 2008 |
Bisphosphonates and osteoporosis.
Topics: Diphosphonates; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Zoledronic Acid | 2002 |